ATE209898T1 - Feste arzneizubereitung - Google Patents

Feste arzneizubereitung

Info

Publication number
ATE209898T1
ATE209898T1 AT98921808T AT98921808T ATE209898T1 AT E209898 T1 ATE209898 T1 AT E209898T1 AT 98921808 T AT98921808 T AT 98921808T AT 98921808 T AT98921808 T AT 98921808T AT E209898 T1 ATE209898 T1 AT E209898T1
Authority
AT
Austria
Prior art keywords
medicinal preparation
solid medicinal
group
reduced
maltitol
Prior art date
Application number
AT98921808T
Other languages
English (en)
Inventor
Toshihiro Shimizu
Masae Sugaya
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15182020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209898(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE209898T1 publication Critical patent/ATE209898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98921808T 1997-05-27 1998-05-26 Feste arzneizubereitung ATE209898T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13672497 1997-05-27
PCT/JP1998/002298 WO1998053798A1 (en) 1997-05-27 1998-05-26 Solid pharmaceutical preparation

Publications (1)

Publication Number Publication Date
ATE209898T1 true ATE209898T1 (de) 2001-12-15

Family

ID=15182020

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921808T ATE209898T1 (de) 1997-05-27 1998-05-26 Feste arzneizubereitung

Country Status (12)

Country Link
US (2) US6299904B1 (de)
EP (1) EP0996424B1 (de)
JP (1) JP2009292843A (de)
KR (1) KR100490969B1 (de)
CN (1) CN1130194C (de)
AT (1) ATE209898T1 (de)
AU (1) AU7451198A (de)
CA (1) CA2286753C (de)
DE (1) DE69802810T2 (de)
ES (1) ES2164424T3 (de)
TW (1) TW580397B (de)
WO (1) WO1998053798A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974366B1 (de) 1997-03-28 2006-10-18 Eisai Co., Ltd. Orale pharmazeutische zusammensetzungen mit reduzierter bitterkeit durch geschmacksmaskiermittel
PT1121103E (pt) 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
ES2237121T3 (es) * 1998-07-28 2005-07-16 Takeda Pharmaceutical Company Limited Preparacion solida disgregable rapidamente.
KR100801236B1 (ko) * 1998-08-28 2008-02-11 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
CA2374760A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
AU782538B2 (en) 1999-10-20 2005-08-04 Eisai Co. Ltd. Method for stabilizing benzimidazole compounds
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1260215E (pt) * 2000-03-01 2009-09-03 Eisai R&D Man Co Ltd Comprimido de desintegração rápida que contém poli(álcool vinílico)
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
DE60110666T2 (de) 2000-03-17 2006-02-02 Shin-Etsu Chemical Co., Ltd. Feste Zubereitung enthaltend niedersubstituierte Hydroxypropylcellulose und Herstellungsverfahren
AU2001267865A1 (en) 2000-06-30 2002-01-14 Yamanouchi Pharmaceutical Co..Ltd. Tablet rapidly disintegrating in mouth and process for producing the same
JP3595765B2 (ja) * 2000-09-27 2004-12-02 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロースを含む乾式直打用基剤
US7799342B2 (en) * 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
NZ527585A (en) * 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
WO2002092058A1 (fr) * 2001-05-15 2002-11-21 Takeda Chemical Industries, Ltd. Preparation solide se desintegrant rapidement
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
WO2003041698A1 (fr) * 2001-11-13 2003-05-22 Kyowa Hakko Kogyo Co., Ltd. Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes
FR2838647B1 (fr) * 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040018990A1 (en) * 2002-07-25 2004-01-29 Harvey Rosner Treatment of obesity
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
ITRM20030485A1 (it) * 2003-10-22 2005-04-23 Tubilux Pharma S P A Composizione a base di citicolina in associazione con vitamine per la prevenzione ed il trattamento di patolgie oculari.
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0416691A (pt) * 2003-11-18 2007-01-30 Boehringer Ingelheim Int forma de preparação farmacêutica sólida
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20050281875A1 (en) * 2003-12-17 2005-12-22 Sovereign Pharmaceuticals, Ltd. Promethazine containing dosage form
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
WO2005070398A2 (en) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
EP1718303A4 (de) * 2004-02-10 2010-09-01 Santarus Inc Kombination eines protonenpumpenhemmers, puffermittels und einem nichtsteroidalen entzündungshemmenden mittel
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
AU2005244162B2 (en) * 2004-05-07 2010-12-09 Thermo Formulations Ltd. Nutritional composition for increasing creatine uptake in skeletal muscle
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
CN100345544C (zh) * 2004-06-10 2007-10-31 范敏华 一种尼麦角林口腔崩解片剂及其制备方法
CN1307973C (zh) * 2004-06-25 2007-04-04 广东天之骄生命科技有限公司 一种血栓通口腔崩解片及其制备方法
CN1318020C (zh) * 2004-06-25 2007-05-30 广东天之骄生命科技有限公司<Del/> 一种养血清脑口腔崩解片及其制备方法
WO2006076097A2 (en) * 2004-12-07 2006-07-20 Nektar Therapeutics Stable non-crystalline formulation comprising losartan
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
CN100457100C (zh) * 2005-12-23 2009-02-04 北京科信必成医药科技发展有限公司 甲氧氯普胺口腔崩解片及其生产方法
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
CA2685131C (en) * 2007-04-26 2015-05-19 Toray Industries, Inc. Stable solid preparation containing 4,5-epoxymorphinan derivative
EP2050440A1 (de) * 2007-10-18 2009-04-22 Krka Stabile und feste pharmazeutische Zusammensetzung mit Candesartan oder pharmazeutisch akzeptablen Formen davon
EP2178510B1 (de) * 2007-07-20 2014-04-09 KRKA, D.D., Novo Mesto Stabile feste pharmazeutische zusammensetzung mit candesartan oder pharmazeutisch annehmbare formen davon
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
FR2930147B1 (fr) * 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
SE533540C2 (sv) 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
WO2010146551A2 (en) * 2009-06-16 2010-12-23 Ranbaxy Laboratories Limited Orally disintegrating compositions comprising antihypertensive agents
TR201007508A1 (tr) * 2010-09-14 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan bileşimler
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP5680607B2 (ja) * 2011-11-10 2015-03-04 大原薬品工業株式会社 安定固形製剤及びその製造法
WO2013115746A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic A production method for (effervescent) pharmaceutical compositions comprising an alpha - glucosidase inhibitor (miglitol) and metformin
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
FR3055800B1 (fr) * 2016-09-15 2020-06-26 Unither Pharmaceuticals Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (de) 2018-07-20 2026-04-01 Lipocine Inc. Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen
FR3095762A1 (fr) * 2020-05-07 2020-11-13 Unither Pharmaceuticals Composition solide à ingestion rapide et déglutition facilitée, sous forme de particules solides non agglomérées, comprenant deux différents types de particules

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5411226A (en) 1977-06-24 1979-01-27 Shin Etsu Chem Co Ltd Disintegratable granule
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
JPH0466538A (ja) 1990-07-04 1992-03-02 Suntory Ltd 抗潰瘍剤
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
JPH05310558A (ja) * 1992-05-07 1993-11-22 Lion Corp 固形製剤組成物
JP3059004B2 (ja) 1992-09-18 2000-07-04 ダイセル化学工業株式会社 アルカリ水溶液に対する溶解性の高い低置換度ヒドロキシプロピルセルロース及びその製造法
JPH06305962A (ja) * 1993-04-21 1994-11-01 Taisho Pharmaceut Co Ltd アトピー性皮膚炎治療剤
JP3502951B2 (ja) 1993-07-06 2004-03-02 大正製薬株式会社 高脂血症治療剤
TW391880B (en) 1994-01-31 2000-06-01 Yamanouchi Pharma Co Ltd An oral soluble type compression moulding and its preparation
SE9501881D0 (sv) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII-receptor antagonists
JPH08310969A (ja) 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
JPH0948726A (ja) * 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
RU2189227C2 (ru) 1996-07-12 2002-09-20 Дайити Фармасьютикал Ко., Лтд. Быстро распадающиеся прессованные в формах материалы и способ их получения
EP0839526A3 (de) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
JP4939680B2 (ja) * 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤

Also Published As

Publication number Publication date
DE69802810T2 (de) 2002-04-18
KR20010020412A (ko) 2001-03-15
TW580397B (en) 2004-03-21
WO1998053798A1 (en) 1998-12-03
DE69802810D1 (de) 2002-01-17
EP0996424A1 (de) 2000-05-03
CA2286753A1 (en) 1998-12-03
JP2009292843A (ja) 2009-12-17
CA2286753C (en) 2006-01-17
CN1130194C (zh) 2003-12-10
CN1257422A (zh) 2000-06-21
AU7451198A (en) 1998-12-30
KR100490969B1 (ko) 2005-05-24
US20010009678A1 (en) 2001-07-26
US6586004B2 (en) 2003-07-01
US6299904B1 (en) 2001-10-09
ES2164424T3 (es) 2002-02-16
EP0996424B1 (de) 2001-12-05

Similar Documents

Publication Publication Date Title
DE69802810D1 (de) Feste arzneizubereitung
MY154010A (en) Rapidly disintegrable solid preparation
WO2000041681A3 (de) ARZNEIFORMULIERUNGEN ENTHALTEND EIN OPIOID UND EINEN α-AGONISTEN
CA2386690A1 (en) Pharmaceutical tramadol salts
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
CA2371940A1 (en) Pregelatinized starch in a controlled release formulation
CA2354057A1 (en) Sustained release tablet containing hydrocolloid and cellulose ether
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
DE69838300D1 (de) Pharmazeutische suspensionstabletten-zusammenstellungen
CA2337046A1 (en) Sustained release pharmaceutical preparation
CA2307018A1 (en) Osmotic medicament releasing system
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
IE871584L (en) Sustained release capsule.
CA2005986A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
HUP0102676A2 (hu) Szilárd, gyorsan széteső cetirizint tartalmazó gyógyszerkészítmények
EP0966966A3 (de) Nefazodon enthaltende Dosierungsform
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
PL346764A1 (en) New oral formulation for 5-ht4
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
IE894049L (en) Therapeutically active substituted benzimidazole and process¹for its preparation
HK19095A (en) Pharmaceutical compositions containing ranitidine
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
CA2376847A1 (en) Complex of eletriptan and a cyclodextrin derivative